Advances in ocular drug delivery: emphasis on the posterior segment
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Recent advances in pharmacological therapies to treat ocular diseases such as glaucoma, age-related macular degeneration, diabetic macular edema and retinal vascular occlusions have greatly improved the prognosis for these diseases. Due to these advances in pharmacological therapy, there is a great deal of interest in minimally invasive delivery methods, which has generated rapid developments in the field of ocular drug delivery. AREAS COVERED: This review will summarize currently available and recent developments for ocular drug delivery to both the anterior and posterior segments. Modes of delivery, including topical, systemic, transcleral/periocular and intravitreal, will be discussed and corresponding examples will be given. This review will highlight the advantages and disadvantages of each mode of delivery and discuss strategies to address these issues. EXPERT OPINION: An ideal therapy should maintain effective levels of drug for the intended duration of treatment following a single application, yet a significant number of months of therapy may be required. There are numerous approaches under investigation to improve treatment options. From the use of novel biomaterial implants and depots for sustained release, to prodrug formations, to iontophoresis to improve drug delivery, the main emphasis will continue to be placed on less invasive, longer acting, sustained release formulations in the treatment of numerous ocular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 4×
“The studies found that both monthly and bimonthly administration of aflibercept produced similar efficacy and safety outcomes as monthly ranibizumab [71,72].”
BackgroundInfluentialRanibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330 · cited 2×
“It was found that needles of length 800 -- 1000 μm and applied pressures of 250 -- 300 kPa provided the most reliable delivery of volumes up to 35 μL [65].”
BackgroundMethodPeriocular routes for retinal drug delivery
Raghava, S., Hammond, M., & Kompella, U. B. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.99 · Cited by 257
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255 · cited 3×
“However, it is important to note that the occurrence of these complications is low and with practiced techniques, rate of incidence is minimal [7].”
BackgroundBiosynthetic Studies of A2E, a Major Fluorophore of Retinal Pigment Epithelial Lipofuscin
Ben-Shabat, S., Parish, C. A., Vollmer, H. R., Itagaki, Y., Fishkin, N., Nakanishi, K., & Sparrow, J. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108981200 · Cited by 214 · cited 1×
“The toxicities include free radical generation upon light exposure, detergentlike properties that can damage RPE cell membrane, inhibition of RPE lysosomes (which leads to drusen formation) and activation of complement factors, a major genetic risk factor for AMD [41].”
BackgroundCannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171 · cited 1×
“It has since been evaluated for suprachoroidal drug delivery of triamcinolone acetide (TA) and bevacizumab in both animals (separately) [60,61] and humans (in combination) [62,63] with positive results.”
Background
Cited by
Thin films as an emerging platform for drug delivery
Karki, S., Kim, H., Na, S.-J., Shin, D., Jo, K., & Lee, J. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2016.05.004 · Cited by 543
Mandal, A., Bisht, R., Rupenthal, I. D., & Mitra, A. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.012 · Cited by 481
“However, relatively frequent injections may still be required for periocular administrations [36].”
BackgroundOcular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“Recent phase I/II trials have shown promise in the treatment of dry eye and uveitis (Patane et al., 2011; Cohen et al., 2012; Kang-Mieler et al., 2014),”
Metadata
- Authors
- Kang-Mieler, J. J., Osswald, C. R., & Mieler, W. F.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2014-06-30
- Volume
- 11
- Issue
- 10
- Pages
- 1647-1660
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2116499331
- Cited by
- 142
- References
- 12
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in ocular drug delivery: emphasis on the posterior segment. https://app.cochat.ai/papers/10.1517/17425247.2014.935338
- The paper
- Kang-Mieler, J. J., Osswald, C. R., & Mieler, W. F. (2014). Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2014.935338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.